NCT00489489View on ClinicalTrials.gov

Phase II Study of Teriflunomide as Adjunctive Therapy to Interferon-beta in Subjects With Multiple Sclerosis

PHASE2CompletedINTERVENTIONAL
Enrollment

118

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

June 30, 2009

Study Completion Date

June 30, 2009

Conditions
Multiple Sclerosis
Interventions
DRUG

Teriflunomide

"Film-coated tablet~Oral administration"

DRUG

Placebo (for Teriflunomide)

"Film-coated tablet~Oral administration"

DRUG

Interferon-β

Powder for reconstitution, of any licensed strength for either intramuscular or subcutaneous injection

Trial Locations (5)

08807

Sanofi-Aventis Administrative Office, Bridgewater

Unknown

Sanofi-Aventis Administrative Office, Laval

Sanofi-Aventis Administrative Office, Berlin

Sanofi-Aventis Administrative Office, Milan

Sanofi-Aventis Administrative Office, Barcelona

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY

NCT00489489 - Phase II Study of Teriflunomide as Adjunctive Therapy to Interferon-beta in Subjects With Multiple Sclerosis | Biotech Hunter | Biotech Hunter